Edition:
United Kingdom

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

59.13USD
8:59pm GMT
Change (% chg)

$-1.65 (-2.71%)
Prev Close
$60.78
Open
$61.00
Day's High
$61.75
Day's Low
$59.04
Volume
213,745
Avg. Vol
290,781
52-wk High
$135.59
52-wk Low
$51.11

Select another date:

Fri, Feb 16 2018

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

BRIEF-Intercept Pharmaceuticals Reports Q4 Net Loss Per Common & Potential Common Share $4.43

* INTERCEPT PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Intercept Announces Updated U.S. Prescribing Information For Ocaliva

* INTERCEPT ANNOUNCES UPDATED U.S. PRESCRIBING INFORMATION FOR OCALIVA® (OBETICHOLIC ACID) TO REINFORCE APPROPRIATE DOSING IN PBC PATIENTS WITH ADVANCED CIRRHOSIS

BRIEF-Intercept Pharma Says Shifting Guidance For Announcement Of Phase 3 Reverse Trial In Nash Patients With Compensated Cirrhosis To Q1 2018

* INTERCEPT PHARMA SAYS SHIFTING GUIDANCE FOR ANNOUNCEMENT OF PHASE 3 REVERSE TRIAL IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS TO Q1 2018 - SEC FILING Source text: (http://bit.ly/2CgH2Og) Further company coverage:

BRIEF-Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​

* Intercept Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-Intercept Pharma posts positive results from Phase 2 AESOP trial

* Intercept announces positive results from Phase 2 AESOP trial evaluating OCA for the treatment of patients with primary sclerosing cholangitis at The Liver Meeting 2017

Intercept does not expect restrictive boxed warning for liver drug

Intercept Pharmaceuticals Inc said on Monday its liver drug, Ocaliva, could carry a boxed warning to help ensure proper dosing but the drugmaker also said it does not expect the updated labeling to be restrictive, sending its shares higher.

UPDATE 2-Intercept does not expect restrictive boxed warning for liver drug

Sept 25 Intercept Pharmaceuticals Inc said on Monday its liver drug, Ocaliva, could carry a boxed warning to help ensure proper dosing but the drugmaker also said it does not expect the updated labeling to be restrictive, sending its shares higher.

Intercept Pharma says possible Ocaliva boxed warning will not be restrictive

Sept 25 Intercept Pharmaceuticals Inc said on Monday an update to the label of its liver drug, Ocaliva, could include a boxed warning to help ensure proper dosing of patients, but added that it did not expect the change to be restrictive.

BRIEF-Intercept Pharmaceuticals comments on Ocaliva safety and dosing in liver disease patients​

* Intercept Pharmaceuticals Inc comments on Ocaliva (obeticholic acid) safety and dosing in primary biliary cholangitis (PBC) patients​

Select another date: